MovDisordV3, Main, Exploration, bibRecord, 004B51

Amantadine is beneficial in restless legs syndrome

Identifieur interne : 004B51 ( Main/Exploration ); précédent : 004B50; suivant : 004B52

Amantadine is beneficial in restless legs syndrome

Auteurs : Virgilio Gerald H. Evidente [États-Unis] ; Charles H. Adler [États-Unis] ; John N. Caviness [États-Unis] ; Joseph G. Hentz [États-Unis] ; Katrina Gwinn-Hardy [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-03.

RBID : ISTEX:D5725319650A7BB42D45825177D5A7A41B51573B

Descripteurs français

Pascal (Inist)
- Amantadine, Chimiothérapie, Evolution, Homme, Impatience membre inférieur syndrome, Somnolence, Stimulant dopaminergique, Toxicité, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Amantadine, Amantadine (administration & dosage), Amantadine (adverse effects), Chemotherapy, Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine agonist, Dose-Response Relationship, Drug, Drug Administration Schedule, Evolution, Female, Human, Humans, Male, Middle Aged, RLS, Restless Legs Syndrome (diagnosis), Restless Legs Syndrome (drug therapy), Restless legs syndrome, Somnolence, Toxicity, Treatment, Treatment Outcome.
MESH :
- chemical , administration & dosage : Amantadine, Dopamine Agents.
- chemical , adverse effects : Amantadine, Dopamine Agents.
- diagnosis : Restless Legs Syndrome.
- drug therapy : Restless Legs Syndrome.
- Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

Twenty‐one patients (mean age 70 yrs) with restless legs syndrome (RLS) were treated with amantadine in an open‐label trial. Amantadine was started at 100 mg per day and was increased every 3–5 days by 100 mg (up to a maximum of 300 mg per day) until significant relief of symptoms or intolerable side effects were experienced. Patients were rated pre‐ and posttreatment using an RLS rating scale (0–10). Each patient also rated the degree of response in a continuous scale from 0% (no improvement) to 100% (complete improvement). Eleven of 21 (52%) had subjective benefit to amantadine, with degree of response ranging from 25%–100% (mean 69%) among responders. Six had 95%–100% improvement. The RLS score for all 21 patients dropped from a mean (± standard deviation) of 9.8 ± 0.6 (range, 8–10) pretreatment to 6.6 ± 3.8 (range, 0–10) posttreatment (p = 0.001). The duration of response was 0–13 months (mean, 3.6 ± 4.5), with nine responders still remaining on the drug as of last follow up. The mean effective dose was 227 mg per day. The most common side effects were drowsiness (3), fatigue (2), and insomnia (2); only two stopped amantadine because of side effects. We conclude that amantadine is an effective and well‐tolerated drug for RLS.

Url:

https://api.istex.fr/document/D5725319650A7BB42D45825177D5A7A41B51573B/fulltext/pdf

DOI: 10.1002/1531-8257(200003)15:2<324::AID-MDS1020>3.0.CO;2-4

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amantadine is beneficial in restless legs syndrome</title>
<author><name sortKey="Evidente, Virgilio Gerald H" sort="Evidente, Virgilio Gerald H" uniqKey="Evidente V" first="Virgilio Gerald H." last="Evidente">Virgilio Gerald H. Evidente</name>
</author>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
</author>
<author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
</author>
<author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name>
</author>
<author><name sortKey="Gwinn Ardy, Katrina" sort="Gwinn Ardy, Katrina" uniqKey="Gwinn Ardy K" first="Katrina" last="Gwinn-Hardy">Katrina Gwinn-Hardy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D5725319650A7BB42D45825177D5A7A41B51573B</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200003)15:2<324::AID-MDS1020>3.0.CO;2-4</idno>
<idno type="url">https://api.istex.fr/document/D5725319650A7BB42D45825177D5A7A41B51573B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A66</idno>
<idno type="wicri:Area/Istex/Curation">002A66</idno>
<idno type="wicri:Area/Istex/Checkpoint">003352</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Evidente V:amantadine:is:beneficial</idno>
<idno type="wicri:Area/Main/Merge">007449</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0177315</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C39</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000082</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C67</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Evidente V:amantadine:is:beneficial</idno>
<idno type="wicri:Area/Main/Merge">007659</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10752586</idno>
<idno type="wicri:Area/PubMed/Corpus">004016</idno>
<idno type="wicri:Area/PubMed/Curation">004016</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004052</idno>
<idno type="wicri:Area/Ncbi/Merge">000235</idno>
<idno type="wicri:Area/Ncbi/Curation">000235</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000235</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Evidente V:amantadine:is:beneficial</idno>
<idno type="wicri:Area/Main/Merge">007195</idno>
<idno type="wicri:Area/Main/Curation">004B51</idno>
<idno type="wicri:Area/Main/Exploration">004B51</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amantadine is beneficial in restless legs syndrome</title>
<author><name sortKey="Evidente, Virgilio Gerald H" sort="Evidente, Virgilio Gerald H" uniqKey="Evidente V" first="Virgilio Gerald H." last="Evidente">Virgilio Gerald H. Evidente</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
<affiliation><wicri:noCountry code="subField">the Philippines</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics Section, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gwinn Ardy, Katrina" sort="Gwinn Ardy, Katrina" uniqKey="Gwinn Ardy K" first="Katrina" last="Gwinn-Hardy">Katrina Gwinn-Hardy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Mayo Clinic Jacksonville, Jacksonville, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-03">2000-03</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="324">324</biblScope>
<biblScope unit="page" to="327">327</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D5725319650A7BB42D45825177D5A7A41B51573B</idno>
<idno type="DOI">10.1002/1531-8257(200003)15:2<324::AID-MDS1020>3.0.CO;2-4</idno>
<idno type="ArticleID">MDS1020</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Amantadine</term>
<term>Amantadine (administration & dosage)</term>
<term>Amantadine (adverse effects)</term>
<term>Chemotherapy</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine agonist</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Evolution</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>RLS</term>
<term>Restless Legs Syndrome (diagnosis)</term>
<term>Restless Legs Syndrome (drug therapy)</term>
<term>Restless legs syndrome</term>
<term>Somnolence</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amantadine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amantadine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Restless Legs Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term>
<term>Chimiothérapie</term>
<term>Evolution</term>
<term>Homme</term>
<term>Impatience membre inférieur syndrome</term>
<term>Somnolence</term>
<term>Stimulant dopaminergique</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty‐one patients (mean age 70 yrs) with restless legs syndrome (RLS) were treated with amantadine in an open‐label trial. Amantadine was started at 100 mg per day and was increased every 3–5 days by 100 mg (up to a maximum of 300 mg per day) until significant relief of symptoms or intolerable side effects were experienced. Patients were rated pre‐ and posttreatment using an RLS rating scale (0–10). Each patient also rated the degree of response in a continuous scale from 0% (no improvement) to 100% (complete improvement). Eleven of 21 (52%) had subjective benefit to amantadine, with degree of response ranging from 25%–100% (mean 69%) among responders. Six had 95%–100% improvement. The RLS score for all 21 patients dropped from a mean (± standard deviation) of 9.8 ± 0.6 (range, 8–10) pretreatment to 6.6 ± 3.8 (range, 0–10) posttreatment (p = 0.001). The duration of response was 0–13 months (mean, 3.6 ± 4.5), with nine responders still remaining on the drug as of last follow up. The mean effective dose was 227 mg per day. The most common side effects were drowsiness (3), fatigue (2), and insomnia (2); only two stopped amantadine because of side effects. We conclude that amantadine is an effective and well‐tolerated drug for RLS.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Arizona</li>
<li>Floride</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Arizona"><name sortKey="Evidente, Virgilio Gerald H" sort="Evidente, Virgilio Gerald H" uniqKey="Evidente V" first="Virgilio Gerald H." last="Evidente">Virgilio Gerald H. Evidente</name>
</region>
<name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
<name sortKey="Gwinn Ardy, Katrina" sort="Gwinn Ardy, Katrina" uniqKey="Gwinn Ardy K" first="Katrina" last="Gwinn-Hardy">Katrina Gwinn-Hardy</name>
<name sortKey="Gwinn Ardy, Katrina" sort="Gwinn Ardy, Katrina" uniqKey="Gwinn Ardy K" first="Katrina" last="Gwinn-Hardy">Katrina Gwinn-Hardy</name>
<name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B51 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B51 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D5725319650A7BB42D45825177D5A7A41B51573B
   |texte=   Amantadine is beneficial in restless legs syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Amantadine is beneficial in restless legs syndrome

Amantadine is beneficial in restless legs syndrome

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.